Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 1/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | USP5 | P45974 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3479958 | 1.00 | MAPK9 (0.54) | MAPK9MAPK10MEN1KMT2AALDH1A1 | |
| SCHEMBL3479829 | 1.00 | MAPK9 (0.54) | MAPK9MAPK10MEN1KMT2AALDH1A1 | |
| SCHEMBL4970549 | 1.00 | MAPK9 (0.54) | MAPK9MAPK10MEN1KMT2AALDH1A1 | |
| SCHEMBL3479841 | 1.00 | MAPK9 (0.54) | MAPK9MAPK10MEN1KMT2AALDH1A1 | |
| SCHEMBL4196889 | 0.99 | MAPK9 (0.53) | MAPK9MAPK10MEN1KMT2AALDH1A1 | |
| SCHEMBL3479805 | 0.99 | MAPK9 (0.54) | MAPK9MAPK10MEN1KMT2AALDH1A1 | |
| SCHEMBL3480655 | 0.97 | MAPK9 (0.55) | MAPK9MAPK10MEN1KMT2AALDH1A1 | |
| SCHEMBL3479962 | 0.97 | MAPK9 (0.57) | MAPK9MAPK10MEN1KMT2AALDH1A1 | |
| SCHEMBL3479954 | 0.97 | MAPK9 (0.57) | MAPK9MAPK10MEN1KMT2AALDH1A1 | |
| SCHEMBL3479861 | 0.97 | MAPK9 (0.57) | MAPK9MAPK10MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322642-B1 | Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of Protein Jun-kinases | MERCK SERONO SA (CH) | 2013-09-04 | — | — | EP | claimed |
| US-7705052-B2 | Sulfonamide derivatives for the treatment of diabetes | MERCK SERONO SA (CH) | 2010-04-27 | — | — | US | claimed |
| US-20070043027-A1 | Sulfonamide derivatives for the treatment of diabetes | APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) | 2007-02-22 | — | — | US | claimed |
| US-20040077854-A1 | Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moietties as inhibitors of protein junkinases | MERCK SERONO SA (CH) | 2004-04-22 | — | — | US | claimed |
| EP-1322642-A2 | sHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES BEARING BOTH LIPOPHILIC AND IONISABLE MOIETIES AS INHIBITORS OF PROTEIN JUNKINASES | Applied Research Systems ARS Holding N.V. (AN) | 2003-07-02 | — | — | EP | claimed |
| WO-2002026733-A2 | sHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES BEARING BOTH LIPOPHILIC AND IONISABLE MOIETIES AS INHIBITORS OF PROTEIN JUNKINASES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2002-04-04 | — | — | WO | claimed |
| EP-1193268-A1 | Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases | Applied Research Systems ARS Holding N.V. (AN) | 2002-04-03 | — | — | EP | claimed |
| US-8658640-B2 | JNK inhibitors for the treatment of endometriosis | MERCK SERONO SA (CH) | 2014-02-25 | — | — | US | disclosed |
| US-8592414-B2 | JNK inhibitors for the treatment of endometriosis | Merck Serono, S.A. (CH) | 2013-11-26 | — | — | US | disclosed |
| US-20130281447-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20130267512-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2013-10-10 | — | — | US | disclosed |
| EP-1322642-B1 | Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of Protein Jun-kinases | MERCK SERONO SA (CH) | 2013-09-04 | — | — | EP | disclosed |
| US-7705052-B2 | Sulfonamide derivatives for the treatment of diabetes | MERCK SERONO SA (CH) | 2010-04-27 | — | — | US | disclosed |
| WO-2007011762-A2 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETREOSIS | LABORATOIRES SERONO S.A. (CH) | 2007-01-25 | — | — | WO | disclosed |
| EP-1663193-A1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | Applied Research Systems ARS Holding N.V. (AN) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005025558-A1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) | 2005-03-24 | — | — | WO | disclosed |
| US-20040077854-A1 | Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moietties as inhibitors of protein junkinases | MERCK SERONO SA (CH) | 2004-04-22 | — | — | US | disclosed |
| EP-1322642-A2 | sHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES BEARING BOTH LIPOPHILIC AND IONISABLE MOIETIES AS INHIBITORS OF PROTEIN JUNKINASES | Applied Research Systems ARS Holding N.V. (AN) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002026733-A2 | sHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES BEARING BOTH LIPOPHILIC AND IONISABLE MOIETIES AS INHIBITORS OF PROTEIN JUNKINASES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2002-04-04 | — | — | WO | disclosed |
| EP-1193268-A1 | Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases | Applied Research Systems ARS Holding N.V. (AN) | 2002-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077854-A1 | Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moietties as inhibitors of protein junkinases | MAPK1, MAP3K1, MAPKAPK2 | MAPK9 9/4885MAPK10 80/4885MEN1 2351/4885 |
| US-20070043027-A1 | Sulfonamide derivatives for the treatment of diabetes | CBR3, INSR, CS | MAPK9 2768/4885MAPK10 1940/4885MEN1 3205/4885 |
| US-20130281447-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | MAPKAPK2, MAPKAPK3, JUN | MAPK9 49/4885MAPK10 40/4885MEN1 3898/4885 |
| US-20130267512-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | MAPKAPK2, MAPKAPK3, JUN | MAPK9 49/4885MAPK10 40/4885MEN1 3898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.